HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2316-2327

  Rath, Kellie S ^a   Naidu, Shan K ^a   Lata, Pushpa ^a   Bid, Hemant K ^b   Rivera, Brian K ^a   McCann, Georgia A ^a   Tierney, Brent J ^a   ElNaggar, Adam C ^a   Bravo, Veronica ^a   Leone, Gustavo ^a   Houghton, Peter ^b   Hideg, Kálmán ^d   Kuppusamy, Periannan ^c   Cohn, David E ^a   Selvendiran, Karuppaiyah ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLIN D2; CYTOTOXIC AGENT; HO 3867; PROTEIN KINASE B; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CHO CELL LINE; CONTROLLED STUDY; DNA BINDING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; EX VIVO STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; PIPERIDONES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899557646     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2433     Document Type: Article

References (27)

1. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, et al. Safe and targeted anticancer efficacy of a novel class of antioxidant- conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radic Biol Med 2010;48: 1228-35.
2. Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 2010;9:1169-79.
3. Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, et al. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 2010;8: 1188-97.
4. Dayton A, Selvendiran K, Meduru S, Khan M, Kuppusamy ML, Naidu S, et al. Amelioration of doxorubicin-induced cardiotoxicity by an anticancer- antioxidant dual-function compound, HO-3867. J Pharmacol Exp Ther 2011;339:350-7.
5. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 2007;282:28609-18.
6. Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res 2013;19:6716-29.
7. Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, et al. DNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res 2014;74:320-9.
8. Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res 2013;73: 1922-33.
9. Zhao W, Jaganathan S, Turkson J. Acell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem 2010;285:35855-65.
10. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012;109:9623-8.
11. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 2006;66:4826-34.
12. Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kalai T, et al. Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 2010;10:1027-32.
13. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997;89:1881-6.
14. Donnerstag B, Ohlenschlager G, Cinatl J, Amrani M, Hofmann D, Flindt S, et al. Reduced glutathione and S-Acetylglutathione as selective apoptosis-inducing agents in cancer therapy. Cancer Lett 1996;110: 63-70.
15. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011;7:428-30.
16. Ahmad N, Gupta S, HusainMM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin Cancer Res 2000;6:1524-8.
17. Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran K. Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. J Ovarian Res 2013;6:35.
18. Vitolo JM, Cotrim AP, Sowers AL, Russo A, Wellner RB, Pillemer SR, et al. The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res 2004;10:1807-12.
19. Hahn SM, Krishna MC, DeLuca AM, Coffin D, Mitchell JB. Evaluation of the hydroxylamine Tempol-H as an in vivo radioprotector. Free Radic Biol Med 2000;28:953-8.
20. Hahn SM, Krishna CM, Samuni A, DeGraff W, Cuscela DO, Johnstone P, et al. Potential use of nitroxides in radiation oncology. Cancer Res 1994;54:2006s-10s.
21. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003;22:5907-14.
22. Verrax J, Taper H, Buc Calderon P. Targeting cancer cells by an oxidant-based therapy. Curr Mol Pharmacol 2008;1:80-92.
23. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 2004;18:2183-94.
24. Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL, Yamada K, et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 2002;62:307-12.
25. Mitchell JB, Krishna MC, Kuppusamy P, Cook JA, Russo A. Protection against oxidative stress by nitroxides. Exp Biol Med 2001;226:620-1.
26. Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, et al. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A 2006;103:3914-9.
27. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kalai T, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011;12:837-45.